334 Aidisheng Road
Zhangjiang High-tech Park
24 articles with Viva Biotech
Viva Biotech 2022 Partnership Summit was successfully held.
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
Viva Biotech Holdings announced that during the year ended December 31, 2021, the revenue of the Group increased significantly to RMB2,104.1 million from RMB697.0 million for the corresponding period last year, representing a YoY increase of approximately 201.9%, gross profit increased substantially from RMB304.9 million for the corresponding period last year to RMB651.0 million, representing a YoY increase of 113.5%.
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
Viva Biotech Holdings and XLement, invested and incubated by Viva BioInnovator, are committed to the production of oral COVID-19 drugs and virus test, contributing to the fight against the COVID-19 pandemic.
Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2021 (the "Reporting Period"), revenue of the Group increased significantly to RMB1,026.5 million from RMB197.6 million for the corresponding period last year
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
Viva Biotech declared that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics.
Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology
Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou.
The Group's Revenue Surged by 115.7% YoY Revenue from the CFS B usiness I ncreased S ignificantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion
Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders
March 2 nd -6 th , 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leaders.
Viva Biotech's Online Investor Day was successfully hosted on December 8, 2020. The management team conducted an online dialogue with nearly 400 investors, focusing on the company's strategy, personnel plans, technology platforms, integration strategic plans, investment incubation, and more.
Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities
Viva Biotech Co., Ltd. entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interest in SYNthesis med chem Limited, at the consideration of approximately US$ 80 million.
Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program
Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones. The pursuit of a convenient, oral PCSK9-based therapy has bee
Revenue Grew by 39% YOY Adjusted Net Profit Rose by 25% YOY Backlog Amount Surged by Approximately 138.2% with Proactive Construction of Comprehensive One-Stop Drug Servicing Platform
Viva Biotech and Langhua Pharmaceutical Reached the Strategic Acquisition Agreement, Accelerating the Escalation of the Service Chain of Innovative Drug Industry
On August 9th, 2020, Viva Biotech Co., Ltd. entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 80% of the equity interest in Zhejiang Langhua Pharmaceutical Co., Ltd, at the Consideration of RMB 2,560 million.
Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups
Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech Ltd., a world-leading structure-based drug discovery platform announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.
Viva Biotech and Schrödinger Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based drug discovery by generating de novo crystal structures of high-value ta
Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
Collaboration aims to enable discovery of first-in-class therapeutic candidates
On 11 June 2020, Viva BioInnovator successfully held its 1st Demo Day e-congress.
Viva Biotech Holdings announced its annual results for the twelve months ended 31 December 2019.
The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held in Beijing.